{"id":7596,"date":"2025-12-06T08:00:09","date_gmt":"2025-12-06T07:00:09","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7596"},"modified":"2025-12-18T20:00:08","modified_gmt":"2025-12-18T19:00:08","slug":"phase-3-sequoia-6-year-long-term-data-of-zanubrutinib-vs-bendamustine-plus-rituximab-in-tn-cll-sll","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7596\/phase-3-sequoia-6-year-long-term-data-of-zanubrutinib-vs-bendamustine-plus-rituximab-in-tn-cll-sll\/","title":{"rendered":"Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN SLL\/CLL) with continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study"},"content":{"rendered":"","protected":false},"template":"","post-tag":[760,704,886,885,673,628,594,781,777,858,563,595,845,542],"class_list":["post-7596","congress-resource","type-congress-resource","status-publish","hentry","post-tag-american-society-of-hematology","post-tag-ash","post-tag-bendamustine-rituximab","post-tag-br","post-tag-btk-inhibitor","post-tag-btki","post-tag-chronic-lymphocytic-leukemia","post-tag-cll-sll","post-tag-del17p","post-tag-ltfu","post-tag-sequoia","post-tag-small-lymphocytic-lymphoma","post-tag-treatment-naive-cll-sll","post-tag-zanubrutinib","congress_resource_type-poster","content_type-reading","disease_state-chronic-lymphocytic-leukemia","disease_state-small-lymphocytic-lymphoma","molecule-zanubrutinib"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":0,"key_data_presentation":true,"key_data_presentation_only":false,"key_data_presentation_prioritization":140,"tags":[704,760,781,594,595,845,777,563,858,542,628,673,885,886],"visible_tags":[704,781,542],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\nThe SEQUOIA study compared zanubrutinib to bendamustine plus rituximab in newly diagnosed chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) patients, including those with high-risk genetic features such as del(17p). After six years of follow-up, zanubrutinib helped patients live longer without disease progression and fewer patients had to switch to a new treatment. Zanubrutinib may help overcome poor prognosis typically associated with high-risk genetic features as the outcomes for patients with del(17p) were comparable to those without del(17p). The safety profile remained generally favorable and consistent over time.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\nThe SEQUOIA study compared zanubrutinib to bendamustine plus rituximab in newly diagnosed chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) patients, including those with high-risk genetic features such as del(17p). After six years of follow-up, zanubrutinib helped patients live longer without disease progression and fewer patients had to switch to a new treatment. Zanubrutinib may help overcome poor prognosis typically associated with high-risk genetic features as the outcomes for patients with del(17p) were comparable to those without del(17p). The safety profile remained generally favorable and consistent over time.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_phase-3-sequoia-6-year-long-term-data-of-zanubrutinib-vs-br-in-tn-cll-sll.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295850","authors":[6577],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN SLL\/CLL) with continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Check out the ASH 2025 poster on phase 3 SEQUOIA 6-year long-term data on zanubrutinib vs bendamustine + rituximab in TN CLL\/SLL by Constantine S. Tam et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/10\/ASH2025_phase-3-sequoia-6-year-long-term-data-of-zanubrutinib-vs-br-in-tn-cll-sll.jpeg\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-sequoia-6-year-long-term-data-of-zanubrutinib-vs-bendamustine-plus-rituximab-in-tn-cll-sll\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295850\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-06\",  \r\n  \"keywords\": [\"sequoia study\", \"phase 3 sequoia study in tn cll\/sll\", \"zanubrutinib bendamustine rituximab clinical research\", \"SEQUOIA trial 6-year outcomes\", \"phase 3 SEQUOIA data in tn cll\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Constantine S. Tam, MBBS (Hons), MD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN SLL\/CLL) with continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-sequoia-6-year-long-term-data-of-zanubrutinib-vs-bendamustine-plus-rituximab-in-tn-cll-sll\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN SLL\/CLL) with continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Check out the ASH 2025 poster on phase 3 SEQUOIA 6-year long-term data on zanubrutinib vs bendamustine + rituximab in TN CLL\/SLL by Constantine S. Tam et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-sequoia-6-year-long-term-data-of-zanubrutinib-vs-bendamustine-plus-rituximab-in-tn-cll-sll\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/6577"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/886"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/885"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/673"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/628"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/542"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/858"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/563"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/777"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/845"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/595"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/594"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/781"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7596"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}